liver function tests; chest tightness and chest pain.While the ADRs were not identical, in all four patients there was a common ADR reported with both piperacillin/tazobactam and ceftolozane/tazobactam.Three of these patients retrialed ceftolozane/tazobactam and tolerated well.Conclusion: A significant proportion of patients with previous ADR's to piperacillin-tazobactam appear to tolerate treatment with ceftolozane/ tazobactam.
These findings suggest that user education and software enhancement has improved time intervals between ARs, with increasing proportions of patients having intervals within the optimal time period.Further research will analyse site-specific clustering of time intervals outside the ideal 9-15-month range.